Literature DB >> 21345169

Inflammatory risk factors and pathologies associated with Alzheimer's disease.

M Sastre1, J C Richardson, S M Gentleman, D J Brooks.   

Abstract

The importance of inflammatory processes in Alzheimer's disease (AD) progression has been confirmed during the past decade by the intensive investigation of inflammatory mediators in the brain of AD patients as well as by the genetic and drug manipulation of animal models of AD. Imaging studies have revealed that the activation of microglia occurs in early stages of the disease, even before plaque and tangle formation, and is correlated with early cognitive deficits. In this review, we analyze how different risk factors, such as trauma, stroke, infection, and metabolic diseases can lead to an acceleration of the inflammatory response in the AD brain and to an increased risk of developing this disorder. The use of imaging techniques for early detection of glial activation which offer the advantage of investigating how potential anti-inflammatory therapies may influence disease progression and levels of cognition is also discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21345169     DOI: 10.2174/156720511795256062

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  23 in total

Review 1.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 2.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

3.  Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer's disease brains and human microglia.

Authors:  D G Walker; A M Whetzel; L-F Lue
Journal:  Neuroscience       Date:  2014-10-05       Impact factor: 3.590

4.  I2-Imidazoline Ligand CR4056 Improves Memory, Increases ApoE Expression and Reduces BBB Leakage in 5xFAD Mice.

Authors:  Bibiana C Mota; Nathan Ashburner; Laura Abelleira-Hervas; Liyueyue Liu; Robertas Aleksynas; Lucio Claudio Rovati; Gianfranco Caselli; Magdalena Sastre
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 5.  Etiology and pathogenesis of late-onset Alzheimer's disease.

Authors:  Brian J Balin; Alan P Hudson
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

Review 6.  The role of neuroinflammation in dementias.

Authors:  Giuseppe Pasqualetti; David J Brooks; Paul Edison
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

7.  Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease.

Authors:  David Tweedie; Ryan A Ferguson; Kelly Fishman; Kathryn A Frankola; Henriette Van Praag; Harold W Holloway; Weiming Luo; Yazhou Li; Luca Caracciolo; Isabella Russo; Sergio Barlati; Balmiki Ray; Debomoy K Lahiri; Francesca Bosetti; Nigel H Greig; Susanna Rosi
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

8.  Microglia function in Alzheimer's disease.

Authors:  Egle Solito; Magdalena Sastre
Journal:  Front Pharmacol       Date:  2012-02-10       Impact factor: 5.810

9.  Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease.

Authors:  Izumi Maezawa; David Paul Jenkins; Benjamin E Jin; Heike Wulff
Journal:  Int J Alzheimers Dis       Date:  2012-05-22

10.  Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia.

Authors:  Catarina Gomes; Raquel Ferreira; Jimmy George; Rui Sanches; Diana I Rodrigues; Nélio Gonçalves; Rodrigo A Cunha
Journal:  J Neuroinflammation       Date:  2013-01-30       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.